Prior studies have shown that chemotherapy and second generation ALK inhibitors help treat crizotinib-resistant non-small-cell lung cancer. However, chemotherapy has multiple side effects, including fatigue and myelosuppression. Alectinib is shown to have prolonged activity in comparison to certinib or brigatinib. This evidence concerns the gene ALK and non-small cell lung carcinoma.